Rigel Pharmaceuticals (RIGL) EBITDA Margin (2010 - 2026)
Rigel Pharmaceuticals' (RIGL) quarterly EBITDA Margin came in at 20.21% in Q1 2026, down 374.0% year-on-year from 7.37% in Q1 2025, and down 39.13% quarter-over-quarter from 33.19% in Q4 2025.
Rigel Pharmaceuticals (RIGL) EBITDA Margin (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' EBITDA Margin history runs 16 years deep, the most recent figure standing at 20.21% for Q1 2026.
- On a quarterly basis, EBITDA Margin fell 374.0% year-over-year to 20.21% in Q1 2026; TTM through Mar 2026 was 41.56%, a 1993.0% increase from a year earlier, with the FY2025 full-year figure at 42.63%, up 2914.0% from the prior year.
- EBITDA Margin retreated to 20.21% in Q1 2026 per RIGL's latest filing, from 33.19% in the prior quarter.
- Across five years, EBITDA Margin topped out at 60.09% in Q2 2025 and bottomed at 156.92% in Q1 2022.
- The 5-year median for EBITDA Margin is 4.05% (2022), against an average of 8.64%.
- Biggest YoY gain for EBITDA Margin was 10900 bps in 2022; the steepest drop was 20846 bps in 2022.
- Year by year, EBITDA Margin stood at 4.05% in 2022, then surged by 35 bps to 5.49% in 2023, then surged by 426 bps to 28.92% in 2024, then advanced by 15 bps to 33.19% in 2025, then sank by 39 bps to 20.21% in 2026.
- Per Business Quant, the three latest RIGL EBITDA Margin figures stand at 20.21% (Q1 2026), 33.19% (Q4 2025), and 40.91% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Rigel Pharmaceuticals | 674.25 Mn | 527.57 Mn | 54.21 Mn | 20.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.21% |
| Dec 31, 2025 | 33.19% |
| Sep 30, 2025 | 40.91% |
| Jun 30, 2025 | 60.09% |
| Mar 31, 2025 | 23.95% |
| Dec 31, 2024 | 28.92% |
| Sep 30, 2024 | 25.41% |
| Jun 30, 2024 | 1.21% |
| Mar 31, 2024 | -23.59% |
| Dec 31, 2023 | 5.49% |
| Sep 30, 2023 | -15.87% |
| Jun 30, 2023 | -19.59% |
| Mar 31, 2023 | -48.81% |
| Dec 31, 2022 | 4.05% |
| Sep 30, 2022 | -82.12% |
| Jun 30, 2022 | -43.48% |
| Mar 31, 2022 | -156.92% |
| Dec 31, 2021 | -104.94% |
| Sep 30, 2021 | -91.84% |
| Jun 30, 2021 | -49.68% |